Clinical Trial Update: A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations [Phase 1, Phase 2]

View source ↗

Summary

Regeneron's DB-OTO, an AAV-based gene therapy, is being evaluated in Phase 1/2 for congenital hearing loss due to biallelic OTOF mutations and is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Otoferlin-related Deafness

Drugs mentioned

• DB-OTO

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | Phase 1, Phase 2 | Status: RECRUITING